US patent granted for Tumorad®
Spago Nanomedical AB (publ) announce today that the United States Patent and Trademark Office (USPTO) has granted the company´s patent application comprising product protection for Tumorad® in the USA.
Tumorad® is based on nanoparticles loaded with a radioisotope and holds potential to become a new treatment of solid tumors. Earlier this year the USPTO issued a preliminary approval by means of a Notice of Allowance. The USPTO has now informed Spago Nanomedical that the patent was approved on June 19.
The patent, with the title “Nanostructures and applications thereof”, has been assigned patent number US 9,999,963 and is valid until year 2035.
The approval means that Spago Nanomedical holds product protection for Tumorad® in one of the strategically most important markets for radionuclide therapies. Further approvals in other territories, e.g. EU and Japan, are pending.
For further information, contact Mats Hansen, CEO Spago Nanomedical AB, +46 767 764294, firstname.lastname@example.org.
Spago Nanomedical (AktieTorget Stockholm: SPAG) develops nanomaterials for cancer diagnostics and therapy. The company´s development activities are primarily focused on the cancer selective MRI-contrast agent SpagoPix, and the Tumorad®-project for cancer selective radionuclide therapy of cancer. The business concept of Spago Nanomedical is to develop projects from explorative to regulatory preclinical or early clinical phase, and then out-license or enter partnership for continued development of the projects to market launch. Spago Nanomedical collaborates with well-established and reputable patent consultants to continuously strengthen the intellectual property protection of the projects.
Tumorad® is a new type of radionuclide therapy based on Spago Nanomedical´s proprietary nanoparticles and a therapeutically relevant radioisotope for tumor selective radiation therapy of cancer. Access to new therapies is essential for effective treatment of many forms of cancer. Tumorad® holds potential for treatment of aggressive and inaccessible tumors, as monotherpay or in synergy with other treatment types.
For further information, see www.spagonanomedical.se.
The information in this press release is such that Spago Nanomedical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU, 596/2014). The information was submitted for publication, through the agency of the contact person set out above, on 26 June, 2018.